Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006558 | 0.97 | KMT2A (0.44) | KMT2AALDH1A1MAPTRAB9ANR1H2 | |
| SCHEMBL2006561 | 0.88 | KMT2A (0.44) | KMT2AALDH1A1MAPTRAB9AGAA | |
| SCHEMBL1996986 | 0.86 | NR1H2 (0.45) | KMT2AALDH1A1RAB9ANR1H2NR1H3 | |
| SCHEMBL2001656 | 0.83 | NR1H2 (0.53) | ALDH1A1MAPTNR1H2NR1H3GAA | |
| SCHEMBL30411787 | 0.78 | NR1H2 (0.47) | ALDH1A1MAPTRAB9ANR1H2NR1H3 | |
| SCHEMBL1996988 | 0.76 | MEN1 (0.39) | KMT2AALDH1A1MAPTRAB9ANR1H2 | |
| SCHEMBL2001237 | 0.75 | NR1H2 (0.51) | ALDH1A1MAPTNR1H2NR1H3GAA | |
| SCHEMBL3487932 | 0.75 | NR1H2 (0.65) | KMT2AALDH1A1MAPTRAB9ANR1H2 | |
| SCHEMBL30411783 | 0.74 | NR1H2 (0.41) | KMT2AALDH1A1MAPTNR1H2NR1H3 | |
| SCHEMBL2006332 | 0.74 | NR1H2 (0.41) | KMT2AALDH1A1NR1H2NR1H3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | KMT2A 2880/4885ALDH1A1 2568/4885MAPT 2119/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | KMT2A 2880/4885ALDH1A1 2568/4885MAPT 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.